Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial

Next Previous
Trial Profile

Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Cerebral haemorrhage
  • Focus Therapeutic Use
  • Acronyms FASTEST

    • Most Recent Events

    • 24 Sep 2019 Planned End Date changed from 1 Jan 2026 to 1 Aug 2026.
    • 24 Sep 2019 Planned primary completion date changed from 1 Jan 2025 to 1 Aug 2025.
    • 24 Sep 2019 Planned initiation date changed from 1 Jan 2020 to 1 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top